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ABSTRACT 
Recent environmental sampling around a landfill site in the UK demonstrated that unidentified 
xenoestrogens were present at higher levels than control sites; that these xenoestrogens were 
capable of super-activating (resisting ligand-dependent antagonism) the murine variant 2 ERβ and 
that the ionic liquid 1-octyl-3-methylimidazolium chloride (M8OI) was present in some samples.  To 
determine whether M8OI was a contributor to the xenoestrogen pool in the soils, activation of 
human estrogen receptors by M8OI was examined.  M8OI activated the human ERα in MCF7 cells in 
a dose-response manner.  These effects were inhibited by the ER antagonist ICI182780; occurred in 
the absence of any metabolism of M8OI and were confirmed on examination of ER-dependent 
induction of trefoil factor 1 mRNA in MCF7 cells.  M8OI also super-activated the murine variant 2 
ERβ in a murine hepatopancreatobiliary cell line.  The human ERβ was not activated by M8OI when 
expressed in HEK293 cells.  These data demonstrate that M8OI is a xenoestrogen capable of 
activating the human ERα and super-activating the murine variant 2 ERβ.  
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1. Introduction 
Recent studies from this laboratory applied cell-based in vitro toxicity studies to screen for chemicals 
present in environmental samples such as soil and water.  Using this approach, it was shown that for 
an urban area in the North East of the UK, chemicals activating the aryl hydrocarbon receptor (AhR) 
or peroxisome proliferator activated receptor alpha (PPARα) - e.g. by polyaromatic hydrocarbons 
and surfactant pollutants respectively - were widely present in the soils naturally and/or through 
anthropomorphic activity.  In contrast, chemicals that activated the human estrogen receptor alpha 
(ERα) were at higher levels in soils around a landfill site compared to control soils from the region 
[1,2]. 
Two sampling sites down-wind of the landfill waste site also contained a chemical that was toxic to 
an hepatocyte progenitor cell line [2].  The soil extracts from these sites inhibited mitochondrial 
electron transport and induced apoptosis [2].  The identity of the chemical was determined to be the 
ionic liquid M8OI [2].  Ionic liquids are relatively recently developed solvents that are liquid at 
ambient temperatures yet also non-volatile.  For this reason, ionic liquids have been proposed as a 
new class of “green solvents” [3]. 
Since the two sampling sites containing M8OI also showed high estrogenic (ERα-activating) activity 
[2], we hypothesised that M8OI is an activator of ERs and its presence in these two sampling sites 
may have contributed – in part - to the high estrogenic activity of extracts from these sampling sites.   
There are 2 ER genes in man - ERα and estrogen receptor beta (ERβ) [4].  In complementary work, 
we have recently shown that soil-derived unidentified chemical(s) are capable of “super-activating” 
a variant (v2) murine ERβ in pancreatohepatobiliary cells, in that the receptor resists antagonism by 
the antagonist ICI182780 (whereas activation by 17β estradiol [E2] remains readily antagonised [1]).  
The ability of M8OI to activate the human ERβ has therefore also been examined. 
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2. Materials and methods 
 
2.1.  Materials and plasmids 
M8OI was purchased from Sigma (Poole, UK).  The (ERE)3-pGL3promoter and pcDNA3.1-mERβv2 
(encoding the mouse ERβ variant 2 transcript) construct was originally prepared and validated as 
previously described [5,1].  A pcDNA3.1 construct encoding a FLAG-tagged human ERβ originally 
constructed by the Srinivas laboratory [6], was obtained via Adgene (plasmid # 35562). 
 
2.2. Cell culture, transfection and dual luciferase assays 
The human breast cancer MCF7 cell line (obtained from Dr Katherine Rennie, Newcastle University), 
human embryonic kidney 293 cell line (HEK293, purchased from the European Collection of Cell 
Cultures [ECACC, Porton Down, UK]) and murine cholangiocyte 603B cell line (a gift from Dr Yedidya 
Saiman, Mount Sinai School of Medicine, New York) were all cultured in low glucose Dulbecco’s 
Modified Eagles Medium (Sigma, Dorset, UK), supplemented with 10% (v/v) foetal bovine serum 
(Sigma) and 80 U/ml of penicillin and streptomycin.  The human H69 cholangiocyte cell line [7] was 
routinely expanded in 3:1 (v/v) ratio of DMEM and Nutrient F12 Ham’s medium supplemented with 
180µM adenine, 2nM triiodothyronine, 5.5µM epinephrine, 1µM hydrocortisone, 10% v/v FCS, 1x 
Insulin/transferrin/selenium (Gibco) and 1 x Pen/Strep (Lonza).  All cell lines were maintained in a 
humidified atmosphere at 37°C in 5% CO2 in air.  MCF7 cells constitutively expressing ERα [5] were 
transiently transfected with (ERE)3-pGL3promoter [5] and RL-TK (Promega, UK) - to control for 
transfection efficiency - at a ratio of 10:1 using Effectene reagent (Qiagen, Manchester, UK), 
according to the manufacturer’s instructions.  All other cell lines - cultured in 24-well plates - were 
transiently transfected with 0.25 μg total DNA per well (pcDNA3.1 expression vector encoding the 
cDNAs for either the FLAG-tagged human ERβ or mERβv2; the estrogen-responsive (ERE)3-
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pGL3promoter reporter gene luciferase construct [5] and RL-TK (Promega, UK) - to control for 
transfection efficiency - at a ratio of 6:6:1 using polyethylenimine (Sigma, Poole, UK) for the MCF7 
and HEK293 cells and Effectene reagent (Qiagen, Manchester, UK), for the 603b cells according to 
the manufacturer’s instructions.   Twenty four hours after transfection, cells - where applicable - 
were pre-treated with ER antagonists for 6 hrs before being treated with estrogens or potential 
xenoestrogens from 1000-fold concentrated stocks in in DMSO or PBS.  Following treatment for 24 
hours, Firefly and Renilla luciferase activities were determined using a Dual-Glo luciferase assay kit 
(Promega, UK) as previously described [5].  Since the mERβv2 exhibits near complete constitutive 
activity when expressed in 603B cells [1,8], cells transfected with the pcDNA3.1 construct encoding 
the mERβv2 were pre-treated with the ER antagonist ICI182780 for 6 hrs followed by five wash steps 
with large volumes of sterile PBS to reduce the levels of antagonist. Cells were then treated with 
estrogens or potential xenoestrogens from 1000-fold concentrated stocks in DMSO or PBS in the 
absence, and where indicated, in the presence of ICI182780. 
Mouse hepatocytes were isolated via a two-step collagenase perfusion and hepatocyte isolations 
essentially as previously detailed [9].  Hepatocytes (typically > 90% viable as determined by trypan 
blue exclusion [9]) were then cultured on collagen-coated 6 well plates in William’s medium E 
supplemented with 10% (v/v) FCS, 80u/ml penicillin, 80µg/ml streptomycin, 10nM dexamethasone 
and 1µg/ml insulin.  Cells were cultured overnight in an humidified atmosphere at 37°C in 5% CO2 in 
air.  The medium was then aspirated and cells were washed in sterile PBS and subsequently cultured 
as above without the addition of FCS. 
 
2.3.  Metabolism of M8OI. 
Culture medium was aspirated and the cells were washed 3 times with sterile PBS (1.37M NaCl, 27 
mM KCl, 100 mM phosphate pH 7.4) prior to incubation with M8OI in 0.10M NaCl, 5.4mM KCl, 
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0.34mM Na2HPO4 12H2O, 0.44mM KH2PO4, 20mM glucose, 1mM CaCl2, 40mM NaHCO3, 4mM 
glutamine, 100µM L-alanine, 100µM L-asparagine, 100µM L-aspartic acid, 100µM L-glutamic Acid, 
100µM glycine, 100µM L-proline and 100µM L-serine (pH 7.4 when gassed with 5% CO2 in air).  As a 
control, M8OI was incubated identically in a cell-free culture vessel.  At various time points, 
incubation medium was centrifuged to remove any cellular material and acidified with 0.1 volumes 
1% phosphoric acid. Acid soluble material analysed by HPLC using a Shimadzu LC-10AD liquid 
chromatograph using authentic M8OI as standard using a Diamonsil C18 (4.6×150mm, 5μm) column 
(Sigma) maintained at 50°C and a mobile phase flow rate of 1 mL/min.  The mobile phase consisted 
of A [0.1% w/v phosphoric acid (aq)] and B [acetonitrile] and sample constituents were separated 
using the following gradient conditions: 90% A : 10% B changing to 10% A : 90% B from 0 - 15 mins; 
10% A : 90% B between 15 and 35 mins; 10% A : 90% B changing to 90% A : 10% B from 35 - 40 mins 
followed by a wash at 90% A : 10% B from 40 – 55 mins.  Elution was monitored at 211nm. 
 
2.4.  TFF1 mRNA expression determined via qRT-PCR 
MCF7 cells were exposed to estrogens or other chemicals for 24 hours.  The cells were then washed 
in ice-cooled PBS and total RNA was isolated using Trizol (Invitrogen, Paisley, UK) following the 
manufacturer’s instructions.  RNA was quantified by UV spectrophotometry and TFF1 mRNA and 18S 
rRNA levels were determined by qRT-PCR using the Applied Biosystem PowerUp SYBR Green master 
mix and StepONE RT-PCR system machine using primers and essentially as previously described [5]. 
 
2.5.  MTT assays. 
Thiazolyl blue tetrazolium bromide (MTT) reduction was used to screen for cell viability by replacing 
culture media with fresh media containing 0.5mg/ml MTT and incubating for between 2-4 hours.  
The medium was then replaced with an equal volume of isopropanol and after mixing, absorbance 
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was determined at 570nm (with background absorbance at 690nm also determined and reading 
subtracted from reading at 570nm).  Results are expressed as percentage absorbance relative to 
vehicle treated cells. 
 
2.6.  Statistical analyses. 
For a study with 3 or more conditions with 1 independent variable, a one-way ANOVA followed by a 
Bonferroni post-hoc test was performed.  For a study with 3 or more conditions with 2 independent 
variables, a two-way ANOVA followed by Bonferroni post-hoc test was performed.  For testing the 
difference between 1 independent variable with one variation in treatment, the Student’s T test was 
used.  In all cases, significant difference (2 tailed) was judged at the p<0.05 level.  
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3. Results 
 
3.1 M8OI activates the human ERα  
To determine whether M8OI (for structure, see Fig. 1) is a human ERα activator, MCF7 cells 
transfected with an ER-responsive reporter construct were exposed to M8OI or known ER activators 
E2 (an endogenous estrogen) or ethinylestradiol (EE, a synthetic estrogen).  Fig. 2a demonstrates 
that M8OI activated the human ERα in a dose-responsive manner with significant measurable 
activation over control occurring at concentrations of at least 25µM.  Figure 2A also demonstrates 
that the ER antagonist ICI182780 [10] inhibited M8OI and E2 or EE reporter gene activity in cell 
extracts, supporting a role for the ERα in mediating the effects of M8OI on reporter gene induced 
expression.  Figure 2b and 2c indicate that there was no detectable metabolism of M8OI over a 24 
hour period – in contrast to a low level of disappearance in cultures of mouse hepatocytes – 
suggesting that M8OI itself rather than a metabolite was responsible for the activation of the ERα in 
MCF7 cells. 
The human ERα transcriptional effects of M8OI were further confirmed through quantitative RT-PCR 
analyses of trefoil factor 1 (TFF1) mRNA expression.  Fig. 3a demonstrates a marked and significant 
dose-response increase in TFF1 expression in MCF7 cells exposed to M8OI, with a peak at 10µM and 
robust block in induction when cells were co-treated with ICI182780.  The cause of the reduction in 
TFF1 transcription between 10 and 25µM M8OI was occasionally also observed with ERα/(ERE)3-
pGL3promoter-dependent luciferase expression.  Fig. 3b indicates that M8OI was toxic to MCF7 cells 
on the basis of significant reduced MTT activity at concentrations of 5µM or greater.  The toxic 
effects of M8OI therefore likely ablated its estrogenic effect in MCF7 cells and underestimated its 
potency to activate the human ERα.  
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3.2.  M8OI is a super-activator of the mouse ERβ variant 2 receptor. 
The mouse generates 2 ERβ proteins by alternative splicing, with variant 2 (orthologous to the 
human ERβ protein) lacking an in-frame exon in the coding region of variant 1 (resulting in a variant 
2 protein lacking variant 1 amino acids 383–400 [1]).  Figure 4a demonstrates, using a mouse 
hepatopancreatobiliary cell line, that M8OI acts as a super-activator of the murine ERβ variant 2 
receptor since M8OI receptor activation was not blocked by the antagonist ICI182780 in contrast to 
when the receptor was activated by E2 or EE.   
To our knowledge, a human cell line expressing transcriptionally functionally-detectable ERβ (in the 
absence of ERα) is not available.  Therefore, to determine whether M8OI is an activator of the 
human ERβ, HEK293 cells were transiently transfected with an expression construct encoding the 
human ERβ in order to generate cells expressing the receptor protein.  Figure 4b demonstrates that 
M8OI failed to activated the human ERβ in HEK293 cells.  Similar results were also also observed 
when these studies were repeated in the human H69 cholangiocyte cell line (data not included). 
 
4.0  Discussion 
This study was conceived from a project seeking to identify potential environmental xenobiotic 
triggers for primary biliary cholangitis (PBC), an auto-immune chronic liver disease characterised by 
bile duct inflammation and destruction.  PBC incidence is most common in post-menopausal women 
and is associated with genetic pre-dispositions [11,12], however, it is thought that xenobiotic 
exposure(s) trigger the disease [13-16].  PBC is associated with a loss of tolerance to the lipoic acid-
conjugated regions of the mitochondrial branched chain α keto acid dehydrogenase complex and 
anti-mitochondrial antibodies in patient sera [17,18].  Thus, one potential trigger for PBC may be 
exposures to chemicals that structurally and chemically mimic lipoic acid, and may therefore be 
capable of enzymatic incorporated into PDC-E2 in place of lipoic acid [17,18].  However, an 
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estrogenic activity may increase the likelihood of a sustained injury since estrogens at elevated levels 
are widely recognised to be hepatotoxic primarily through a cholesatic effect. 
Since the environmental study identified M8OI in a region that also contained unidentified 
xenoestrogens at higher levels than control sample sites, we hypothesised that M8OI could be a 
component of the chemicals in the environmental samples activating the ERs.  We demonstrate in 
this report that M8OI is a xenoestrogen capable of activating the human ERα receptor.  Although we 
demonstrate that M8OI is capable of super-activating the murine ERβ variant 2 protein, activation of 
any nature was not seen in the human orthologue ERβ.  Super-activation therefore has currently 
only been observed in murine cholangiocyte cells and may be specific to these cells or species.  
Alternatively, given that response element and ligands (agonists or antagonists) are independent 
modulators of ER conformation and that ligands modulate ER-cofactor interaction [19], it may be 
that both HEK293 and H69 cholangiocytes differ to 603b cells in the presence of a co-factor 
permissive for super-activation. 
Xenoestrogens are exogenous chemicals that mimic the activity of estrogens.  A xenoestrogen may 
be a chemical that interacts with a variety of receptors mediating the biological effect of estrogens 
as hormones, although other mechanisms could have an estrogenic effect (e.g. by disrupting 
estrogen bioavailability).  These data indicate that M8OI has the potential to act as a xenoestrogen in 
man through at least an interaction with the ERα.  In the context of the liver and PBC, this estrogenic 
activity – be it from M8OI or to related imidazolium-based solvents - may be relevant to a 
xenobiotic-induced trigger for PBC.  ERα is expressed in hepatocytes whereas both ERα and ERβ are 
expressed in cholangiocytes and expression is increased in cholestatic liver injury settings [20,21] .  
Estrogens have been proposed to regulate the expression of factors controlling proliferative (via 
ERα) or apoptotic (via ERβ) responses of cholangiocytes (20,21).  
Thus, M8OI – in addition to directly inhibiting liver cell oxidative phosphorylation in the 
mitochondria [2] and readily being metabolised to a carboxylic acid metabolite with structural 
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similarity to lipoic acid by human hepatocytes [2] – may also be capable of disrupting normal bile 
duct homeostasis through interaction with the ERα in man. 
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Fig. 1.  Comparison of the chemical structures of 17β estradiol and M8OI. 
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Fig. 2.  M8OI activates the human ERα in MCF7 cells.  A, luciferase reporter gene (ERE)3-
pGL3promoter assay in MCF7 cells. Cells were transiently transfected as outlined in the methods 
section. Following transfection, cells were pre-treated for 6 hours with either 100nM ICI182780 or 
vehicle (DMSO, 0.1% v/v).  Cells were then treated with indicated compounds in continued presence 
of ICI182780 or vehicle for a further 24 hours prior to analysis. Data are the mean and SD of 3 
separate determinations from the same experiment, typical of 3 separate experiments. *Significantly 
different (p<0.05) versus DMSO vehicle-treated (0μM) cells using two-way ANOVA followed by 
Bonferroni post-hoc test. $Significantly different (p<0.05) versus equivalent treatments in the 
absence of ICI182780 using Student’s t-test (two-tailed). B, Typical HPLC chromatogram of 100μM 
M8OI in STIM buffer.  C, Disappearance of M8OI in MCF7 and mouse hepatocyte culure media.  Cells 
were incubated with 100μM of M8OI in STIM buffer for 24 hours and samples taken over a 24-hour 
period and analysed by HPLC as in B.  Data are the mean and SD of 3 separate experiments. 
*Significantly different (p<0.05) versus time zero using one-way ANOVA followed by a Bonferroni 
post-hoc test. 
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Fig. 3.  M8OI induces expression of TFF1 mRNA in MCF7 cells.  A, MCF7 cells were pre-treated with 
100nM ICI182780 or DMSO vehicle (0.1% v/v) as indicated for 6 hours followed by the treatment 
with the indicated compounds in the continued presence of ICI182780 or vehicle.  After 24 hours, 
total RNA was extracted and TFF mRNA and 18S rRNA expression determined. TFF mRNA was  
normalised to 18S rRNA expression and fold change expressed relative to control vehicle-treated 
cells.  Data are the mean and SD of 3 separate experiments.  *Significantly different normalised TFF1 
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expression (p<0.05) versus 0μM (DMSO vehicle) treated cells using two-way ANOVA followed by 
Bonferroni post-hoc test. $Significantly different (p<0.05) versus equivalent treatments in the 
absence of ICI182780 using Student’s t-test (two-tailed).  B, MTT reduction in MCF7 cells following 
24 hours incubation with the indicated concentration of M8OI. Results are expressed as the mean 
and SD of 3 separate determinations and are expressed as a percentage of 0.1% (v/v) DMSO vehicle.   
*Significantly different (p<0.05) versus DMSO vehicle-treated (0μM) cells using one-way ANOVA 
followed by Bonferroni post-hoc test. 
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Fig. 4.  M8OI is a super-activator of the mouse ERβ variant 2 but does not activate the human ERβ.  
A, luciferase reporter gene (ERE)3-pGL3promoter assay in 603B cells co-transfected with the 
expression construct encoding mERβv2. Cells were transiently transfected as outlined in the 
methods section. Following transfection, cells were pre-treated for 6 hours with 100nM ICI182780 to 
de-activate constitutively-active mERβv2.  At time zero, cells were washed with PBS and treated with 
the indicated compounds for a further 24 hours prior to analysis. Data are the mean and SD of 3 
separate determinations from the same experiment, typical of 3 separate experiments. *Significantly 
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different (p<0.05) versus DMSO vehicle-treated (0μM) cells using two-way ANOVA followed by 
Bonferroni post-hoc test. $Significantly different (p<0.05) versus equivalent treatments in the 
absence of ICI182780 using the Student’s t-test (two-tailed). B, luciferase reporter gene (ERE)3-
pGL3promoter assay in HEK293 cells co-transfected with the expression construct encoding hERβ. 
Cells were transiently transfected as outlined in the methods section. Following transfection, cells 
were pre-treated for 6 hours with 100nM ICI182780 or vehicle (DMSO, 0.1% v/v). Cells were then 
treated with indicated compounds in continued presence of ICI182780 or vehicle for a further 24 
hours prior to analysis. Data are the mean and SD of 3 separate determinations from the same 
experiment, typical of 3 separate experiments. *Significantly different (p<0.05) versus DMSO vehicle-
treated (0µM) cells using two-way ANOVA followed by Bonferroni post-hoc test. $Significantly 
different (p<0.05) versus equivalent treatments in the absence of ICI182780 using Student’s t-test 
(two-tailed). 
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